Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

The recruitment status of this study is unknown because the information has not been verified recently.

Verified August 2006 by Huazhong University of Science and Technology.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Huazhong University of Science and Technology

ClinicalTrials.gov Identifier:

NCT00360763

First received: August 4, 2006

Last updated: NA

Last verified: August 2006

History: No changes posted

Purpose

The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in patients with hypertension. ATR-AA which can blocked by ARB may play a role in the pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE inhibitor imidapril.

Condition	Intervention	Phase
Hypertension	Drug: candesartan cilexetil	Phase 4

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Candesartan Candesartan cilexetil

U.S. FDA Resources

Further study details as provided by Huazhong University of Science and Technology:

Estimated Enrollment:	600
Estimated Study Completion Date:	December 2006

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Hypertension (2 grade)

Exclusion Criteria:

Secondary hypertension
Known sensitivity or intolerance to an angiotensin II receptor antagonist or ACE inhibitor
Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00360763

Locations

China, Hubei
Department of Cardiology, Wuhan Union Hospital	Recruiting
Wuhan, Hubei, China, 430022
Contact: Yu-Hua Liao, Doctor 00862785726376 yumiaowei@vip.sina.com

Sponsors and Collaborators

Huazhong University of Science and Technology

Investigators

Study Director:

Yu-Hua Liao

Union Hospital, Tongji Medical College

More Information

Publications:

Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res. 2002 Jul;25(4):641-6.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Wei F, Jia XJ, Yu SQ, Gu Y, Wang L, Guo XM, Wang M, Zhu F, Cheng X, Wei YM, Zhou ZH, Fu M, Liao YH; SOT-AT1 Study Group. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart. 2011 Mar;97(6):479-84. Epub 2011 Feb 4.

ClinicalTrials.gov Identifier:	NCT00360763 History of Changes
Other Study ID Numbers:	UH-01
Study First Received:	August 4, 2006
Last Updated:	August 4, 2006
Health Authority:	China: Food and Drug Administration

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Candesartan cilexetil
Candesartan
Angiotensin II Type 1 Receptor Blockers

Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 19, 2013

To Top